The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Novel applications for fedratinib: MDS/MPN overlap syndromes, CNL, and combination therapies
In this interview, Alexander Coltoff, MD, Medical University of South Carolina, Charleston, SC, briefly outlines some of the potential novel applications for fedratinib, including myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, chronic neutrophilic leukemia (CNL), and combination therapies. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so for fedratinib it does have this nice kind of kinome profile where it inhibits both JAK1, JAK2, but also FLT3 and some other proteins like BRD4 that are implicated in inflammation and some disease activity. So one of my colleagues here Andrew Kuykendall from Moffitt has discussed a study that he led looking at fedratinib in patients with MDS/MPN overlap syndromes, as well as chronic neutrophilic leukemia...
Yeah, so for fedratinib it does have this nice kind of kinome profile where it inhibits both JAK1, JAK2, but also FLT3 and some other proteins like BRD4 that are implicated in inflammation and some disease activity. So one of my colleagues here Andrew Kuykendall from Moffitt has discussed a study that he led looking at fedratinib in patients with MDS/MPN overlap syndromes, as well as chronic neutrophilic leukemia. And I think it’ll be really important to kind of harness these other effects of the JAK inhibitors that we have as the field moves more towards combination therapies. So all the JAK inhibitors are not created equal, and can we utilize the unique inhibition profile of fedratinib to maybe pair it with good second agents to deepen the responses that we see.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speaking fees: Incyte, Blueprint Medicines, Sobi; Advisory Boards: PharmaEssentia, Blueprint Medicines.
